Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
3 Months Ended 9 Months Ended 175 Months Ended
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Revenues:        
Grant revenue $ 2,400 $ 200,400 $ 873,300 $ 12,963,100
Collaboration revenue          2,283,600
Other          1,123,500
Total revenues 2,400 200,400 873,300 16,370,200
Operating expenses:        
Research and development 1,305,600 3,092,200 3,561,000 29,217,100
Acquired in-process research and development          7,523,200
General and administrative 1,547,900 2,430,200 3,569,100 29,548,600
Total operating expenses 2,853,500 5,522,400 7,130,100 66,288,900
Loss from operations (2,851,100) (5,322,000) (6,256,800) (49,918,700)
Other expenses, net:        
Interest expense, net (455,500) (611,700) (1,637,600) (10,053,200)
Change in put and note extension option and warrant liabilities    (357,800) 78,000 (776,300)
Loss on early extinguishment of debt (1,193,500) (3,537,000) (1,193,500) (4,730,500)
Other income          47,500
Loss before income taxes (4,500,100) (9,112,900) (9,165,900) (63,878,600)
Income taxes    (3,700) (1,600) (20,500)
Net loss (4,500,100) (9,116,600) (9,167,500) (63,899,100)
Deemed dividend on Series A Preferred stock    (7,125,000)    (7,125,000)
Net loss attributable to common stockholders (4,500,100) (16,241,600) (9,167,500) (71,024,100)
Basic and diluted net loss per common share $ (0.28) $ (0.93) $ (0.65)  
Weighted average shares used in computing basic and diluted net loss per common share 16,035,861 17,411,993 14,139,007  
Comprehensive loss $ (4,500,100) $ (9,116,600) $ (9,167,500) $ (63,899,100)